Drug Trial Radar · NCT01199965
Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers
Last checked: Nov 19, 2026Latest source record: Jan 9, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Actual
Start
Jan 2010
Primary completion
Apr 2010
Study completion Apr 2010
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- Collaborators
- MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
- First posted
- Sep 13, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Compare the pharmacokinetics of Dihydroergotamine Mesylate (DHE) delivered by oral inhalation (MAP0004) or Intravenous (IV) DHE in smokers versus non-smokers. Identify whether there are clinically significant differences in the tolerability of MAP0004 between smokers and non-smokers.
Conditions
- Healthy Subjects
Interventions
MAP0004Drug
1.0mg MAP0004 via inhalation at Visit 2 or 3 as per protocol
IV DHEDrug
IV DHE administered at Visit 2 or 3 as per protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax of Dihydroergotamine After MAP0004 and IV DHE Administration in Smokers Versus Non-smokersTime frame: 48 hours
- AUC(0-48) of Dihydroergotamine After MAP0004 and IV DHE Administration in Smokers and Non-smokersTime frame: 48 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Simbec Research Limited
Merthyr Tydfil, Merthyr Tydfil, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.